Mechanism tested through convergent perturbations
NAC treatment, dominant-negative and constitutively active Rac1, NOX4 knockdown and overexpression, and two NOX4 inhibitors converge on the ROS–hyperproliferation–DDR pathway.
↳ Results, Figures 1–4
Abstract
Oncogene-induced reactive oxygen species (ROS) have been proposed to be signaling molecules that mediate proliferative cues. However, ROS may also cause DNA damage and proliferative arrest. How these apparently opposite roles can be reconciled, especially in the context of oncogene-induced cellular senescence, which is associated both with aberrant mitogenic signaling and DNA damage response (DDR)-mediated arrest, is unclear. Here, we show that ROS are indeed mitogenic signaling molecules that fuel oncogene-driven aberrant cell proliferation. However, by their very same ability to mediate cell hyperproliferation, ROS eventually cause DDR activation. We also show that oncogenic Ras-induced ROS are produced in a Rac1 and NADPH oxidase (Nox4)-dependent manner. In addition, we show that Ras-induced ROS can be detected and modulated in a living transparent animal: the zebrafish. Finally, in cancer we show that Nox4 is increased in both human tumors and a mouse model of pancreatic cancer and specific Nox4 small-molecule inhibitors act synergistically with existing chemotherapic agents.
Key Claims
Primary findingWell-supported
ROS are indeed mitogenic signaling molecules that fuel oncogene-driven aberrant cell proliferation. However, by their very same ability to mediate cell hyperproliferation, ROS eventually cause DDR activation.
Possible — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
convergent scavenging, proliferation-gating, and DDR experiments directly support the proposed mechanistic sequence
Abstract; Results, Figure 1
SecondaryWell-supported
Oncogenic Ras-induced ROS are produced in a Rac1 and NADPH oxidase (Nox4)-dependent manner.
Rac1 and NOX4 gain- and loss-of-function interventions provide convergent necessity and sufficiency evidence
Abstract; Results, Figures 2–4
SecondaryWell-supported
Ras-induced ROS can be detected and modulated in a living transparent animal: the zebrafish.
in vivo DHE detection and reduction by NAC and NOX4 inhibition directly identify and modulate the signal
Abstract; Results, Figure 5
SecondaryTentative
Nox4 is increased in both human tumors and a mouse model of pancreatic cancer and specific Nox4 small-molecule inhibitors act synergistically with existing chemotherapic agents.
tissue expression is cross-system, but synergy rests on one cell line and a directionally contradictory IC50 statement
Abstract; Results, Figures 6–7
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Proliferation requirement directly isolated
Oncogenic Ras raises ROS in both proliferating and contact-inhibited cells, but DDR activation appears only in proliferating cells, directly testing the proposed replication-dependent mechanism.
↳ Results, “ROS accumulation upon oncogene expression,” Figure 1e
Clinical complexity traced into interpretation
The Discussion explains that ROS inhibition may suppress established cancer-cell proliferation yet permit earlier oncogene-expressing cells to expand without engaging OIS, making disease stage consequential.
↳ Discussion, final paragraph
Limitations
IC50 direction contradicts synergy claim
The combination is described as strongly synergistic, yet the text reports a four- to sixfold increase in gemcitabine IC50, ordinarily indicating reduced drug potency. This materially clouds the therapeutic conclusion.
↳ Results, Figure 7b and Supplementary Figure S7O
Therapeutic evidence lacks model breadth
Gemcitabine combination testing is restricted to Panc1 cells, with no second PDAC line or in vivo tumor-treatment experiment. The pancreatic tissue results are observational rather than intervention evidence.
↳ Results, Figures 6–7
Statistical and synergy analyses remain thin
The paper reports Student’s two-tailed t-tests across many endpoints without explicit multiplicity correction, and the drug-combination methods describe IC50 fitting rather than a formal synergy analysis.
↳ Materials and Methods, Drug Combination Treatment and Statistical Analysis
Nabu Commentary
The core score is driven by convergent mechanistic experiments linking Ras, Rac1, NOX4, ROS, proliferation, and DDR activation across Figures 1–4. Zebrafish, mouse, and human tissue observations broaden the biological setting, but they do not validate therapeutic efficacy across disease models. The combination experiment in Figure 7 is limited to Panc1 cells and the stated increase in gemcitabine IC50 conflicts with the claim of synergy. The Discussion adds value by tracing how ROS inhibition could have opposite consequences before and after OIS bypass.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Strong3.8
Confidence highContribution
3.9
The study meaningfully advances the ROS–senescence account by proposing that ROS-driven hyperproliferation produces replication-associated DDR activation and by locating Rac1 and NOX4 in that pathway. Its therapeutic extension remains narrower than the mechanistic contribution because combination testing is confined to Panc1 cells.
Abstract; Results, Figures 1–7; Discussion, paragraphs 1–6
“by their very same ability to mediate cell hyperproliferation, ROS eventually cause DDR activation”
Methodological Rigour
3.7
Gain- and loss-of-function perturbations, inactive and empty-vector controls, orthogonal ROS probes, and several DDR readouts provide convergent tests of the mechanism. Statistical analysis is limited to t-tests, while combination treatment lacks a formal synergy analysis and independent disease-model replication.
Results, Figures 1–4 and 7; Materials and Methods, ROS Detection, Drug Combination Treatment, and Statistical Analysis
Reporting
3.7
The argument progresses coherently from ROS dependence through Rac1/NOX4 mediation to animal and cancer observations. Reporting is materially reduced by describing enhanced combination activity while reporting an increased gemcitabine IC50.
Abstract; Results, Figure 7b; Discussion, paragraph 6
“it increased the half-maximal inhibitory concentration (IC50) of gemcitabine by four- to sixfold”
Positioning
3.8
The Introduction and Discussion engage the dual mitogenic and genotoxic roles of ROS and trace the stage-dependent risks of ROS inhibition into therapeutic interpretation. Potential inhibitor off-target effects and the single-cell-line scope of the combination result receive limited explicit treatment.
Introduction, paragraphs 2–3; Discussion, final three paragraphs
“ROS scavenging may allow oncogene-expressing cells to multiply or reduce in number”
Lower confidence on Methodological Rigour, Reporting — domain match limited.
Reliability
Concerns4 of 4 checks
Internal CoherenceConcern
The central mechanistic account is internally coherent, but the therapeutic combination result contains a material direction-of-effect conflict. The reported increase in gemcitabine IC50 is incompatible with the accompanying claim of enhanced potency unless an unreported convention or textual error explains it.
Research ConductClean
Ethics approval is declared for the human archival samples and animal experiments, with no text-grounded conduct concern identified. The absence of preregistration, data availability, code availability, and a supplied conflict-of-interest statement is recorded without elevating reliability for this study type and era.
Flags: 1 declared / 5 total
Reference IntegrityNoted
61 of 65 checkable references verified
66 references in manuscript 1 are books, websites or datasets — counted, but not index-checkable
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 11 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Demonstrated
The therapeutic proposition reaches laboratory proof of concept in Panc1 cells, while zebrafish experiments validate biology rather than antitumor treatment. No in vivo tumor efficacy, toxicity, dosing, or optimized candidate evaluation is reported.
Results, Figures 5 and 7; Materials and Methods, Drug Combination Treatment
AI-generated, human-governed. Something look off? Contact us to request a review.